Effect of clipyridamole during acute stroke: exploring antithrombosis and neuroprotective benefits

被引:9
作者
d'Esterre, C. D. [1 ,2 ,3 ]
Lee, T-Y [2 ,3 ]
机构
[1] Robarts Res Inst, Imaging Res Labs, London, ON N6A 5K8, Canada
[2] Univ Western Ontario, Dept Med Biophys, London, ON, Canada
[3] Lawson Hlth Res Inst, London, ON, Canada
来源
INNATE INFLAMMATION AND STROKE | 2010年 / 1207卷
关键词
stroke; inflammation; dipyridamole; neuroprotection; antiplatelet drug; CEREBRAL-BLOOD-FLOW; SECONDARY PREVENTION; ANTIPLATELET AGENTS; ORAL DIPYRIDAMOLE; ENDOTHELIAL-CELLS; INFLAMMATION; ADENOSINE; BRAIN; ISCHEMIA; PHARMACOKINETICS;
D O I
10.1111/j.1749-6632.2010.05801.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Currently, many stroke-prone individuals take antithrombotic drugs, which have known antiplatelet properties, to decrease stroke incidence. There is now evidence that this regimen could also reduce stroke severity through neuroprotective, nonplatelet mechanisms that include anti-inflammatory processes. Inflammation was found to play an important role in atherosclerosis/thrombosis development and acute stroke progression. In light of these findings, prevention strategies that target inflammatory mediators are under investigation. A common secondary stroke prevention therapeutic, dipyridamole, has shown promise for reducing stroke recurrence without increasing bleeding. In addition to its antiplatelet ability, dipyridamole has positive effects on vascular endothelium and inflammation. This review explores the effect of dipyridamole during acute stroke, revealing its potential use for improving poststroke clinical outcome.
引用
收藏
页码:71 / 75
页数:5
相关论文
共 37 条
  • [1] TNF-α and IL-8 in acute stroke and the modulation of these cytokines by antiplatelet agents
    Al-Bahrani, Ali
    Taha, Safa
    Shaath, Husain
    Bakhiet, Moiz
    [J]. CURRENT NEUROVASCULAR RESEARCH, 2007, 4 (01) : 31 - 37
  • [2] Is there a link between aspirin therapy and stroke severity?
    Bath, P. M.
    [J]. NATURE CLINICAL PRACTICE NEUROLOGY, 2007, 3 (01): : 12 - 13
  • [3] Pharmacokinetics of Extended-Release Dipyridamole following Administration through a Gastrostomy Tube An Open-Label, Case-Control, Two-Centre Study
    Batista, Leonardo M.
    Crandell, David
    Lima, Fabricio O.
    Greer, David M.
    [J]. CLINICAL DRUG INVESTIGATION, 2010, 30 (07) : 483 - 488
  • [4] The effect of dipyridamole on vascular cell-derived reactive oxygen species
    Chakrabarti, S
    Vitseva, O
    Iyu, D
    Varghese, S
    Freedman, JE
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 315 (02) : 494 - 500
  • [5] Dipyridamole, cerebrovascular disease, and the vasculature
    Chakrabarti, Subrata
    Freedman, Jane E.
    [J]. VASCULAR PHARMACOLOGY, 2008, 48 (4-6) : 143 - 149
  • [6] Reactive oxygen radicals in signaling and damage in the ischemic brain
    Chan, PH
    [J]. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2001, 21 (01) : 2 - 14
  • [7] Intertwining of thrombosis and inflammation in atherosclerosis
    Croce, Kevin
    Libby, Peter
    [J]. CURRENT OPINION IN HEMATOLOGY, 2007, 14 (01) : 55 - 61
  • [8] Dipyridamole for preventing stroke and other vascular events in patients with vascular disease - An update
    De Schryver, Els L. L. M.
    Algra, Ale
    van Gijn, Jan
    [J]. STROKE, 2008, 39 (04) : 1397 - 1398
  • [9] European stroke prevention study .2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke
    Diener, HC
    Cunha, L
    Forbes, C
    Sivenius, J
    Smets, P
    Lowenthal, A
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 1996, 143 (1-2) : 1 - 13
  • [10] PHARMACOKINETICS OF ORAL DIPYRIDAMOLE (PERSANTINE) AND ITS EFFECT ON PLATELET ADENOSINE UPTAKE IN MAN
    DRESSE, A
    CHEVOLET, C
    DELAPIERRE, D
    MASSET, H
    WEISENBERGER, H
    BOZLER, G
    HEINZEL, G
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1982, 23 (03) : 229 - 234